{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:48:39Z","timestamp":1782222519778,"version":"3.54.5"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chylorrhea after breast-conserving surgery is exceedingly rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We describe the case of a 38-year-old woman with refractory, isolated, cystic leakage from a breast cavity. All conventional interventions failed, whereas thoracic-duct ligation paradoxically increased chylous fluid drainage. Next-generation sequencing (NGS) of the extratumoral tissue revealed a somatic PIK3CA mutation, which led to a diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>To our knowledge, this is the first reported case linking PROS to chylorrhea after breast-conserving surgery, aggravated by duct ligation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Refractory surgical complications should be discussed and managed by a multidisciplinary team to identify or rule out occult diseases. These occult states that may be explained by somatic mosaic mutations are usually characterized by insidious or absent symptoms and are often diagnosed incidentally following surgical trauma or injury. In such contexts, precise genetic testing and targeted therapies may be pivotal and effective for diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fsurg.2026.1820981","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:49:30Z","timestamp":1782218970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: First report of PIK3CA-related overgrowth spectrum revealed by refractory chylorrhea after breast-conserving surgery: failed thoracic-duct ligation"],"prefix":"10.3389","volume":"13","author":[{"given":"Yue","family":"Wan","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Department of Quality Control, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Jiaozhou Maternity and Child Health and Family Planning Service Center","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"878645","DOI":"10.3389\/fonc.2022.878645","article-title":"Chylous leakage after breast-conserving surgery and axillary clearance: case report and management strategies","volume":"12","author":"Yin","year":"2022","journal-title":"Front Oncol"},{"key":"B2","first-page":"5","article-title":"Surgical treatment of persisting chylothorax","volume":"9","author":"Andreieshchev","year":"2008","journal-title":"Klin Khir"},{"key":"B3","article-title":"PIK3CA-related Segmental overgrowth","volume-title":"GeneReviews\u00ae","author":"Mirzaa","year":"1993"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/ajmg.a.36552","article-title":"Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum","author":"Keppler-Noreuil","year":"2014","journal-title":"Am J Med Genet A"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jpeds.2014.12.069","article-title":"Lymphatic and other vascular malformative\/overgrowth disorders are caused by somatic mutations in PIK3CA","volume":"166","author":"Luks","year":"2015","journal-title":"J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/ng.2332","article-title":"Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA","volume":"44","author":"Lindhurst","year":"2012","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4293\/108680812X13427982376545","article-title":"Unconventional management of chyloascites after laparoscopic nissen fundoplication","volume":"16","author":"Hwang","year":"2012","journal-title":"JSLS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.36836","article-title":"PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation","author":"Keppler-Noreuil","year":"2015","journal-title":"Am J Med Genet A"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.3390\/cancers13246162","article-title":"Opportunities and limitations of pelvic exenteration surgery","volume":"13","author":"Lampe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","article-title":"Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum","volume":"21","author":"Parker","year":"2019","journal-title":"Genet Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jvs.2019.06.217","article-title":"Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review","volume":"71","author":"Freixo","year":"2020","journal-title":"J Vasc Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.hoc.2019.01.011","article-title":"Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options","volume":"33","author":"Adams","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","article-title":"FDA Approval summary: alpelisib for PIK3CA-related overgrowth spectrum","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S1470-2045(19)30372-9","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer","volume":"20","author":"Stirrups","year":"2019","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s13023-025-03831-z","article-title":"Safety findings from the phase 1\/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome","volume":"20","author":"Eng","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT Pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1820981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:49:32Z","timestamp":1782218972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1820981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":18,"alternative-id":["10.3389\/fsurg.2026.1820981"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2026.1820981","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1820981"}}